此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

PBI-410 在晚期实体瘤中的 1/2 期研究

2026年9月24日 更新者:Biohaven Therapeutics Ltd.

PBI-410 在晚期实体瘤受试者中的首次人体剂量递增和剂量扩展研究 1/2 期

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.

研究概览

详细说明

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510, a Trop-2 directed antibody-drug conjugate (ADC), in participants with previously treated, advanced solid tumors. The study comprises 2 parts: a Phase 1 Dose Escalation and a Phase 2 Dose Expansion. The Phase 1 will investigate the safety and tolerability of BHV-1510 given in monotherapy and given in combination with cemiplimab and identify one or more recommended doses for expansion (RDEs) and the maximum-tolerated dose (MTD) (if one exists). Once the RDE has been established, Phase 2 will open to investigate the preliminary efficacy of BHV-1510 in signal-finding expansion cohorts.

研究类型

介入性

注册 (估计的)

500

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • California
      • Duarte、California、美国、91010
        • 招聘中
        • Site-113
      • La Jolla、California、美国、92093
        • 招聘中
        • Site-112
      • Palo Alto、California、美国、94304
        • 招聘中
        • Site-111
    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20016
        • 招聘中
        • Site-114
    • Florida
      • Miami、Florida、美国、33176
        • 招聘中
        • Site-103
      • Orlando、Florida、美国、32827
        • 招聘中
        • Site-105
      • Tampa、Florida、美国、33612
        • 招聘中
        • Site-115
    • Georgia
      • Augusta、Georgia、美国、30912
        • 招聘中
        • Site-110
    • Michigan
      • Detroit、Michigan、美国、48201
        • 招聘中
        • Site-109
    • Missouri
      • St Louis、Missouri、美国、63108
        • 完全的
        • Site-101
    • New York
      • New York、New York、美国、10021
        • 招聘中
        • Site-117
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73117
        • 招聘中
        • Site-116
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19107
        • 招聘中
        • Site-108
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • 招聘中
        • Site-107
    • Texas
      • Dallas、Texas、美国、75231
        • 招聘中
        • Site-104
    • Utah
      • West Valley City、Utah、美国、84119
        • 招聘中
        • Site-106
    • Virginia
      • Fairfax、Virginia、美国、22031
        • 招聘中
        • Site-102

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  • Male or female participants aged ≥18 years.

  • Unresectable, incurable, locally advanced or metastatic epithelial-origin solid tumor that is refractory to standard therapies, or has no approved standard therapies, or no approved standard therapies at its current treatment stage. If applicable to the tumor type, participants must have received platinum-based chemotherapy, standard of care immunotherapy, and standard of care targeted therapies.

  • Measurable disease (per RECIST 1.1).

  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.

  • Participants have adequate hematologic, renal, liver, and coagulation function as defined by the following (blood transfusion or growth factor support is not allowed within 7 days prior to blood samples that will be used to establish eligibility):

    • Hemoglobin ≥9 g/dL
    • Absolute neutrophil count >1,500/mm3; participants with known Duffy null phenotype who have absolute neutrophil count ≥1,200/mm3 may be enrolled
    • Platelets >100,000/mm3
    • Creatinine clearance ≥50 mL/min measured or estimated using the Cockcroft-Gault formula; 24-hour urine collection is allowed, but not required.
    • Total bilirubin ≤1.5 × upper limit of normal (ULN); participants with known Gilbert's syndrome who have total bilirubin level ≤3×ULN may be enrolled.
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5×ULN (or ≤5×ULN for participants with hepatic metastases)
    • Alkaline phosphatase <2.5×ULN (or ≤5×ULN for participants with hepatic and/or bone metastases)
    • International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN
    • Activated partial thromboplastin time (aPTT) ≤1.5×ULN. Study participants on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for intended use
  • Have recovered (ie, improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.

BHV-1510 in Combination with specific inclusion criteria:

  • histologically or cytologically documented advanced (locally, recurrent, inoperable, cannot betreated with curative intent) or metastatic cancer including Endometrial Carcinoma that is confirmed as proficient mismatch repair (pMMR)
  • received ≤ 2 prior lines of systemic anti-cancer therapy and at most one prior anti-programmed cell death protein 1 (PD-1) (programmed death-ligand 1 [PD-L1]) therapy for advanced/ metastatic disease.

Key Exclusion Criteria:

  • Women who are pregnant or lactating.
  • Clinically significant intercurrent disease.
  • Has symptomatic brain metastases or has had any radiation or surgery for brain metastases within 4 weeks of C1D1.
  • Has clinically significant corneal disease.
  • Requires supplemental oxygen for daily activities.
  • Previous treatment with a Trop-2-targeted therapy, including Trop-2 ADCs.
  • Has a medical history of interstitial lung disease (eg, noninfectious interstitial pneumonia requiring steroid treatment, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis) or current interstitial lung disease or are suspected to have any of these diseases based on imaging at Screening.
  • Any standard cancer therapy (eg, chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment) or experimental therapy within 3 weeks or 5 half-lives, whichever is shorter, prior to C1D1. The interval may be reduced to 2 weeks for bone and visceral metastasis therapy. Any major surgical procedure within 6 weeks prior to C1D1.
  • History of severe hypersensitivity reactions to other monoclonal antibodies or either the drug substances or inactive ingredients of BHV-1510.
  • Has current or previously treated leptomeningeal carcinomatosis.
  • Use of OAP1B1 and OATP1B3 inhibitors within 14 days prior to starting trial.

BHV-1510 in Combination Specific Exclusion Criteria:

  • Hypersensitivity to cemiplimab or any of its excipients or contraindicated to cemiplimab per approved local labeling.
  • Experienced Grade 3 or higher immune-related AEs with prior treatment of anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
  • Prior allogeneic stem cell or solid organ transplantation.
  • Patients with history of myocarditis.
  • Presence of cardiovascular disease

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:BHV-1510 单药治疗剂量递增

BHV-1510 will be administered on Day 1 every 3 weeks

其他名称:
  • GQ1010
  • PBI-410

BHV-1510 will be administered on Day 1 every 2 weeks

其他名称:
  • GQ1010
  • PBI-410

BHV-1510 will be administered on Day 1 and Day 8 every 3 weeks

其他名称:
  • GQ1010
  • PBI-410
实验性的:BHV-1510 与 Cemiplimab 联合剂量递增

BHV-1510 will be administered on Day 1 every 3 weeks

其他名称:
  • GQ1010
  • PBI-410

BHV-1510 will be administered on Day 1 every 2 weeks

其他名称:
  • GQ1010
  • PBI-410

BHV-1510 will be administered on Day 1 and Day 8 every 3 weeks

其他名称:
  • GQ1010
  • PBI-410

cemiplimab (350mg) will be administered as an IV infusion on Day 1 every 3 weeks

cemiplimab (350mg) will be administered as an IV infusion on Day 1 and Day 8 every 3 weeks

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Phase 1: Number of patients with adverse events (AEs)
大体时间:Through study completion, estimated as an average of 47 months

Description: Incidence and severity of AEs, serious adverse events (SAEs) and dose limiting toxicities (DLTs). Severity of AEs will be assessed according to the NCI CTCAE v5.0. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm.

Through study completion, estimated as an average of 47 months
Phase 1: Recommended doses or schedules for expansion (RDEs) and maximum tolerated dose (MTD)
大体时间:Approximately 15 months

Based on tolerability and preliminary antitumor activity. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm.

Approximately 15 months
Phase 2: Objective Response Rate (ORR) for BHV-1510 for monotherapy and in combination with cemiplimab
大体时间:Through study completion, estimated as an average of 47 months

Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1.

Through study completion, estimated as an average of 47 months
Phase 2: Number of patients with AEs for BHV-1510 for monotherapy and in combination with cemiplimab
大体时间:Through study completion, estimated as an average of 47 months

Incidence and severity of AEs, SAEs and DLTs. Severity of AEs will be assessed according to the NCI CTCAE v5.0

Through study completion, estimated as an average of 47 months
Phase 2: Duration of Response (DoR) for BHV-1510 for monotherapy and in combination with cemiplimab
大体时间:Through study completion, estimated as an average of 47 months

Assessed by RECIST v 1.1

Through study completion, estimated as an average of 47 months

次要结果测量

结果测量
措施说明
大体时间
第1阶段和2:BHV-1510的最大血浆浓度(CMAX),总抗体和有效载荷(BHC-0080269)
大体时间:在周期1和3中,最多8个时间点,但不超过22天
在周期1和3中,最多8个时间点,但不超过22天
第1阶段和2:从输注结束到BHV-1510的最后一个可测量浓度(AUCLAST),总抗体和有效载荷的最后一个可测量浓度(AUCLAST),浓度与时间曲线下的面积
大体时间:在周期1和3中,最多8个时间点,但不超过22天
在周期1和3中,最多8个时间点,但不超过22天
第1阶段和2:在BHV-1510的剂量间隔(AUCTAU),总抗体和有效载荷的浓度与时间曲线下的面积
大体时间:在周期1和3中,最多8个时间点,但不超过22天
在周期1和3中,最多8个时间点,但不超过22天
第1阶段和2:消除BHV-1510的半衰期(T1/2),总抗体和有效载荷
大体时间:在周期1和3中,最多8个时间点,但不超过22天
在周期1和3中,最多8个时间点,但不超过22天
第1阶段和第2阶段:BHV-1510的槽浓度(CORTROUGH),总抗体和有效载荷
大体时间:在周期1和3中,最多8个时间点,但不超过22天
在周期1和3中,最多8个时间点,但不超过22天
第2阶段:BHV-1510单药治疗和有效载荷对使用Fridericia校正方法(QTCF)以及其他ECG参数(心率[HR],PR和QRS间隔)的影响对QTC间隔的影响
大体时间:大约15个月
大约15个月
第一阶段和第二阶段:BHV-1510、总抗体及有效载荷浓度-时间曲线下面积外推至无穷大(AUCinf)
大体时间:周期1内最多8个时间点,但不超过22天
周期1内最多8个时间点,但不超过22天
第1和2阶段:BHV-1010静脉给药后的总全身清除率(CL)或皮下给药后的表观总全身清除率(CL/F)以及总抗体
大体时间:最多8个时间点,但不超过周期1和3中的22天
最多8个时间点,但不超过周期1和3中的22天
第一阶段和第二阶段:BHV-1510皮下给药后的生物利用度百分比(%F)与总抗体
大体时间:最多8个时间点,但不超过周期1和周期3的22天
最多8个时间点,但不超过周期1和周期3的22天
第1和2阶段:BHV-1510静脉给药后的稳态分布容积(Vss)或皮下给药后的稳态表观分布容积(Vss/F)与总抗体
大体时间:最多8个时间点,但不超过第1和第3周期的22天
最多8个时间点,但不超过第1和第3周期的22天
Phase 1: ORR
大体时间:Through study completion, estimated as an average of 47 months

Assessed by RECIST v 1.1. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm.

Through study completion, estimated as an average of 47 months
Phase 1: Duration of Response (DoR)
大体时间:Through study completion, estimated as an average of 47 months

Assessed by RECIST v 1.1. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm.

Through study completion, estimated as an average of 47 months
Phase 1 and 2: Immunogenicity of BHV-1510
大体时间:Through study completion, estimated as an average of 47 months

Incidence of ADA at baseline and post-treatment, including ADA titer

Through study completion, estimated as an average of 47 months
Phase 2: Disease control rate (DCR) for BHV-1510 for monotherapy and in combination with cemiplimab
大体时间:Through study completion, estimated as an average of 47 months

Assessed by RECIST v 1.1

Through study completion, estimated as an average of 47 months
Phase 2: Progression free survival (PFS) for BHV-1510 for monotherapy and in combination with cemiplimab
大体时间:Through study completion, estimated as an average of 47 months

Assessed by RECIST v 1.1

Through study completion, estimated as an average of 47 months
Phase 2: Overall survival (OS) for BHV-1510 for monotherapy and in combination with cemiplimab
大体时间:Through study completion, estimated as an average of 47 months

OS is defined as the time period from the start of administration to death due to any cause

Through study completion, estimated as an average of 47 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Chief Medical Officer、Biohaven Pharmaceuticals, Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年4月22日

初级完成 (估计的)

2028年2月1日

研究完成 (估计的)

2028年2月1日

研究注册日期

首次提交

2024年4月22日

首先提交符合 QC 标准的

2024年4月22日

首次发布 (实际的)

2024年4月25日

研究记录更新

最后更新发布 (实际的)

2026年9月28日

上次提交的符合 QC 标准的更新

2026年9月24日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • BHV1510-101 (PBI-410-101)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅